Everest Medicines Ltd. · HKEX:1952
Everest Medicines — Investor Presentation (November 2024)
28 slides from Everest Medicines's investor presentation, November 2024
Slide 1: Corporate Deck November 2024
Corporate Deck November 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Everest Medicines Limited (the “Company” and together with its subsidiaries, the “Group”) solely for information purposes and does not constitute a recommendation regarding the securities of the Group or an offer to sell or issue or the solicitation
Slide 3: Pursuing Asian Leadership Position in Blue Ocean Therapeutic Areas
Pursuing Asian Leadership Position in “Blue Ocean” Therapeutic Areas To be a leading biopharma in Asia Pacific by 2030, we aim to create social impact Vision through our innovative medicine portfolio and sustainable growth. 3 core therapeutic areas with 4 near term products aggregated peak sales pot
Slide 4: Broad Pipeline With Multiple First-in-class or Best-in-class Products
Broad Pipeline With Multiple First-in-class or Best-in-class Products in Our Focus Treatment Areas Everest Clinical Status NDA/BLA Molecule Global Clinical Partner Commercial Right Indication Pre- BLA/NDA approval (Modality) Phase1 Phase2 Phase3 Approval Status clinical Application Greater China, Ap
Slide 5: Fully Integrated Biopharma: Dual Engine Strategy to Value Creation
Fully Integrated Biopharma: Dual Engine Strategy to Value Creation Differentiated portfolio drives Commercial Platform commercial cash flow Leverage commercial platform to • Drive organic revenue growth • Expand pipeline in core therapeutic maximize synergies areas and increase scale and efficiency
Slide 6: 1H 2024: Solid Revenue Growth with Focus on Operating Efficiency
1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet Substantial High gross Significantly Strong cash revenue growth margin1 narrowed non- balance as % of revenue IFRS net loss2 RMB 301.5M RMB 212.6M +158% vs.2H 2023 83% -35% vs.1H 2023 RMB 1.93B Achieved commerc
Slide 7: Strong Sales Growth Driven by NEFECON and XERAVA, Reiterate Full Year Revenue Guidance
Strong Sales Growth Driven by NEFECON® and XERAVA®, Reiterate Our Full Year Revenue Guidance Product revenue (RMB M) +158% Launched in May Continued revenue 2024 ramp up 301.5 167.3M 134.2M 117.0 2H 2023 1H 2024 On track for the full year revenue guidance of 700M RMB 7
Slide 8: Significant Unmet Medical Needs in IgAN Addressed by NEFECON
Significant Unmet Medical Needs in IgAN Addressed by NEFECON® Substantial unmet medical needs in China No approved therapy prior to NEFECON® 5M Current treatment options, such as RAS inhibitors, are non-targeted and used off-label IgAN Patients Current treatment options do not alter disease progress
Slide 9: Results from China Subpopulation Showed Greater NEFECON Treatment Effect
Results from China Subpopulation Showed Numerically Greater NEFECON® Treatment Effect in Kidney Function, Proteinuria and Microhematuria Compared with Global Data ü Chinese subpopulation in control group (RAS inhibitor) showed more rapid deterioration in eGFR and UPCR than global population Mean cha
Slide 10: Global Phase Data: 50% Less Loss of Kidney Function
Global Phase 3 Data Demonstrated 9-month Treatment of Nefecon® Resulted in 50% Less Loss of Kidney Function, Equivalent to Delay in Progression to End Stage Renal Disease by 12.8 Years Efficacy Data 5 Mean absolute change in eGFR from baseline (mL/min/1.73m2) ü Improvement in total 2-year eGFR 0 slo
Slide 11: Global Phase Data Showed Significant UPCR Reduction
Global Phase 3 Data Showed Significant UPCR Reduction, Reaching 51.3% After Treatment Stopped for 3 Months Efficacy Data Percent change in UPCR from 0 ü At 9 month, UPCR was reduced by 33.6% from baseline in the baseline (%) Nefecon® group compared with -20 5.2% in the placebo group. ü At 12 month,
Slide 12: KDIGO 2024 Guideline (Public Review Draft): IgAN Treatment
KDIGO 2024 Guideline (Public Review Draft) : IgAN Treatment • The focus of management in most patients should be to simultaneously： ‒ Prevent or reduce IgA immune complex formation and immune complex-medicated glomerular injury ‒ In parallel, manage the consequences of existing IgAN-induced nephron
Slide 13: Successful Commercial Launch of NEFECON in China
Successful Commercial Launch of NEFECON® in China Successful commercial launch in China by leveraging online and offline innovative approaches Online Traditional prescription hospitals Focused and highly efficient commercial organization ~150 sales representatives 500-700 hospitals >60% of market po
Slide 14: Significant Unmet Clinical Needs and Limited Therapeutic Options for MDR Infections
Significant Unmet Clinical Needs and Limited Therapeutic Options for MDR Infections Substantial unmet medical needs in China Current treatment options cannot fully meet clinical needs Low tissue concentration, High carbapenem resistance rates Tigecycline adverse events, Black Box warning (all-cause
Slide 15: XERAVA Revenue Continues to Grow by Expanding Hospital Coverage
XERAVA® Revenue Continues to Grow by Expanding and Deepening Hospital Coverage Sales reps ~120 Target hospitals ~300 5 3 1 Medical publications New guideline inclusions Core market Treated patients increased by ~300% vs. 2023 2H Non-core market: Hospital listing increased by ~75% vs. 2023 2H CSO par
Slide 16: Etrasimod: Approved in Macau and Expected to Launch in Greater Bay Area in 2H 2024
Etrasimod: Approved in Macau and Expected to Launch in Greater Bay Area in 2H 2024 19 Designated medical institutions in Guangdong approved to use clinically urgently needed drugs that have been marketed in Hong Kong and Macau Effective, oral advanced UC treatment well- Large medical needs in UC in
Slide 17: Pipeline of Products in Renal Diseases Focus
Pipeline of Products in Our Therapeutic Area Focus of Renal Diseases • The clinical pipeline for the treatment of renal diseases are expected to bring new treatment options to ~10M patients with glomerular disease Focal Segmental Minimal Change Glomerulosclerosis Disease (FSGS) (MCD) Membranous 500K
Slide 18: Complementary Products in MDR Infection Treatment
Complementary Products in Our Therapeutic Area Focus of MDR Infection Treatment (Eravacycline) Cefepime-taniborbactam EVER206 (SPR206) First-in-class fluorocycline Best-in-class BL/BLI, with potent antibiotic, broad spectrum and selective inhibitory activity A novel polymyxin derivative with coverag
Slide 19: Dual Engine Approach Towards Building Differentiated Future Pipeline
Dual Engine Approach Towards Building Differentiated Future Pipeline In-licensing Discovery Focus on core therapeutic areas Clinically validated mRNA platform In our focused TAs Focus on late-stage and commercial-stage assets Therapeutic cancer vaccines Focus on commercial and clinical Focus on deli
Slide 20: A Growing Pipeline of Assets with Global Rights
A Growing Pipeline of Assets with Global Rights mRNA platform Personalized Immune- EVER001 cancer TAA cancer modulatory In vivo CAR-T (BTKi) vaccines vaccines cancer vaccines Cancer Indication Membranous Cancer Cancer Cancer /Autoimmune Nephropathy Development Phase 1b data Launched IIT US IND submi
Slide 21: EVER001: A Potent Covalent Reversible BTK Inhibitor
EVER001: A Potent Covalent Reversible BTK inhibitor Suited for Autoimmune Renal Indications Compared with covalent and irreversible BTK inhibitors, EVER001 is potentially BIC with high selectivity while maintaining high potency Large unmet medical needs globally EVER001 1 Reversible covalency 2 Exce
Slide 22: EVER001: Phase 1b Trial Ongoing and Preliminary Data Expected in 2H 2024
EVER001: Phase 1b Trial Ongoing and Preliminary Data Expected in 2H 2024 Phase 1 results in healthy subjects ü EVER001 was generally well-tolerated after single or multiple exposures to healthy subjects, no serious adverse events were reported ü EVER001 exhibited a dose-proportional increase in Cmax
Slide 23: A Fully Integrated and Clinically Validated mRNA Platform
A Fully Integrated and Clinically Validated mRNA Platform Proprietary antigen Proprietary LNP CMC process Self-owned design algorithm delivery system development manufacturing facility ensures high leads to enhanced ensures robust (Jiashan, Zhejiang) expression of target T cell immunity mRNA DS/DP s
Slide 24: EVM16: A Personalized Neoantigen Cancer Vaccine
EVM16: A Personalized Neoantigen Cancer Vaccine Based on Specific Mutations of Cancer Patients Everest Proprietary Neoantigen Prediction Algorithm MHC binding strength/number Differential Epitope/peptide binding immunogenicity Pathogen seq score similarity WT/MT seq EVM16 … change distance MHC I and
Slide 25: EVM14: An Off-the-Shelf Tumor Associated Antigen Vaccine
EVM14: An Off-the-Shelf Tumor Associated Antigen (TAA) Vaccine Advantages of TAA cancer vaccine Good tumor specificity (tumor vs. normal) More T cell epitopes and no HLA restriction Off-the-shelf, well suited for advanced disease Reduced manufacture costs (vs. PCV) Potential for multiple cancer indi
Slide 26: How In Vivo mRNA CAR-T Works and its Advantages
How in Vivo mRNA CAR-T Works and its Advantages ü Targeted LNPs (tLNPs) loaded with modified mRNAs encoding a CAR are decorated with antibodies targeted to T cells and when Advantages of mRNA in vivo CAR-T over autologous bound will be endocytosed and release their cargo. CAR T therapy ü mRNA is sub
Slide 27: Our Priorities in 2H 2024
Our Priorities in 2H 2024 Doctor and patient education, NRDL negotiation, and treatment guideline inclusion Deepen core market penetration and expand CSO partnership Priorities Commercialization in Greater Bay Area, and China NDA submission In-house R&D progress in mRNA therapeutic vaccines Results
Slide 28: Q&A
Q&A CONTACT US: [email protected]
Everest Medicines — Investor Presentation (November 2024) on 6ix